Bradley Foster & Sargent Inc. CT purchased a new position in Solventum Co. (NYSE:SOLV – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 7,973 shares of the company’s stock, valued at approximately $422,000.
Several other large investors have also recently made changes to their positions in the company. Davis Selected Advisers acquired a new stake in shares of Solventum in the second quarter valued at about $273,070,000. Nuance Investments LLC acquired a new position in shares of Solventum during the 2nd quarter worth approximately $115,829,000. Bank of New York Mellon Corp purchased a new stake in shares of Solventum in the second quarter valued at approximately $48,487,000. Dimensional Fund Advisors LP acquired a new stake in shares of Solventum in the second quarter valued at approximately $26,480,000. Finally, Sumitomo Mitsui Trust Holdings Inc. purchased a new position in Solventum during the second quarter worth approximately $24,533,000.
Solventum Price Performance
SOLV opened at $72.32 on Friday. The company has a current ratio of 1.31, a quick ratio of 0.96 and a debt-to-equity ratio of 2.90. The business’s 50-day moving average price is $60.59. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05.
Wall Street Analysts Forecast Growth
SOLV has been the subject of a number of recent research reports. BTIG Research initiated coverage on Solventum in a research note on Thursday, September 5th. They issued a “neutral” rating for the company. Bank of America dropped their price target on shares of Solventum from $70.00 to $60.00 and set a “neutral” rating for the company in a research note on Tuesday, June 25th. The Goldman Sachs Group upped their price objective on Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a report on Monday, August 12th. Argus began coverage on Solventum in a research note on Monday, June 24th. They set a “hold” rating for the company. Finally, Wells Fargo & Company decreased their price target on Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. According to MarketBeat, Solventum presently has an average rating of “Hold” and an average target price of $58.25.
Check Out Our Latest Stock Analysis on Solventum
Solventum Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Read More
- Five stocks we like better than Solventum
- Stock Analyst Ratings and Canadian Analyst Ratings
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What is the Dogs of the Dow Strategy? Overview and Examples
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.